Zhang Hongtuan, Wang Andi, Ma Hui, Xu Yong
National Key Clinical Specialty of Urology, Tianjin Key Lab of Urology, Second Affiliated Hospital of Tianjin Medical University, 23 Pingjiang Road, Hexi District, 300211, Tianjin, China.
Tumour Biol. 2013 Oct;34(5):2929-36. doi: 10.1007/s13277-013-0855-3. Epub 2013 May 25.
Epidemiological studies investigating the association between the insulin receptor substrate 1 (IRS1) gene Gly972Arg (rs1801278) polymorphism and various carcinomas risk reported conflicting results. Thus, a systemic review and meta-analysis of published studies were performed to assess the possible association. A comprehensive search was conducted to identify all eligible studies of IRS1 Gly972Arg polymorphism and cancer risk. Odds ratios (ORs) and 95 % confidence intervals (CIs) were used to assess the strength of the associations. A total of 16 independent studies, including 11,776 cases and 11,654 controls, were identified. When all studies were pooled, we found a significant association between IRS1 Gly972Arg polymorphism and increased cancer risk under dominant model (OR = 1.16, 95 %CI = 1.04-1.30, P = 0.007) and allelic model (OR = 1.16, 95 %CI = 1.02-1.30, P = 0.02). In subgroup analysis based on cancer type, increased cancer risk was found in ovarian cancer (dominant: OR = 1.55, 95 %CI = 1.17-2.05, P = 0.002; allelic: OR = 1.55, 95 %CI = 1.19-2.01, P = 0.001), breast cancer (allelic: OR = 1.12, 95 %CI = 1.00-1.26, P = 0.05), and other cancers (allelic: OR = 1.31, 95 %CI = 1.00-1.71, P = 0.05). When stratified by study types, significant associations were observed in both cohort studies (dominant: OR = 1.25, 95 %CI = 1.06-1.47, P = 0.007; allelic: OR = 1.25, 95 %CI = 1.07-1.46, P = 0.005) and case-control studies (dominant: OR = 1.15, 95 %CI = 1.01-1.31, P = 0.04). In the subgroup analyses by ethnicity, significantly increased cancer risk was suggested among both Caucasians (dominant: OR = 1.13, 95 %CI = 1.02-1.26, P = 0.02; allelic: OR = 1.13, 95 %CI = 1.03-1.25, P = 0.01) and mixed population (dominant: OR = 1.22, 95 %CI = 1.01-1.46, P = 0.04). Our investigations demonstrate that IRS1 Gly972Arg polymorphism was associated with an increased risk of cancer, and additional well-designed studies are warranted to validate these findings.
流行病学研究调查胰岛素受体底物1(IRS1)基因Gly972Arg(rs1801278)多态性与各种癌症风险之间的关联,结果相互矛盾。因此,我们对已发表的研究进行了系统综述和荟萃分析,以评估可能存在的关联。我们进行了全面检索,以确定所有关于IRS1 Gly972Arg多态性与癌症风险的合格研究。采用优势比(OR)和95%置信区间(CI)来评估关联强度。共纳入16项独立研究,包括11776例病例和11654例对照。当汇总所有研究时,我们发现在显性模型(OR = 1.16,95%CI = 1.04 - 1.30,P = 0.007)和等位基因模型(OR = 1.16,95%CI = 1.02 - 1.30,P = 0.02)下,IRS1 Gly972Arg多态性与癌症风险增加之间存在显著关联。在基于癌症类型的亚组分析中,发现卵巢癌(显性:OR = 1.55,95%CI = 1.17 - 2.05,P = 0.002;等位基因:OR = 1.55,95%CI = 1.19 - 2.01,P = 0.001)、乳腺癌(等位基因:OR = 1.12,95%CI = 1.00 - 1.26,P = 0.05)和其他癌症(等位基因:OR = 1.31,95%CI = 1.00 - 1.71,P = 0.05)的癌症风险增加。按研究类型分层时,队列研究(显性:OR = 1.25,95%CI = 1.06 - 1.47,P = 0.007;等位基因:OR = 1.25,95%CI = 1.07 - 1.46,P = 0.005)和病例对照研究(显性:OR = 1.15,95%CI = .01 - 1.31,P = 0.04)中均观察到显著关联。在按种族进行的亚组分析中,白种人(显性:OR = 1.13,95%CI = 1.02 - 1.26,P = 0.02;等位基因:OR = 1.13,95%CI = 1.03 - 1.25,P = 0.01)和混合人群(显性:OR = 1.22,95%CI = 1.01 - 1.46,P = 0.04)的癌症风险均显著增加。我们的研究表明,IRS1 Gly972Arg多态性与癌症风险增加相关,需要更多精心设计的研究来验证这些发现。